Guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer;Guía de la EAU sobre el cáncer de próstata. Parte II: tratamiento del cáncer de próstata avanzado, recidivante y resistente a la castración EAU

Actas Urologicas Espanolas

Volumn 35, Issue 10, 2011, Pages 565-579

  Mottet, N ^a   Bellmunt, J ^b   Bolla, M ^c   Joniau, S ^d   Mason, M ^e   Matveev, V ^f   Schmid, H P ^g   Van Der Kwast, T ^h   Wiegel, T ⁱ   Zattoni, F ^j   Heidenreich, A ^k  

^a Clinique Mutualiste de la Loire   (France)

^b HOSPITAL DEL MAR   (Spain)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d Hospital Universitario   (Belgium)

^e VELINDRE CANCER CENTRE   (United Kingdom)

^f Centro de Investigación Del Cáncer   (Russian Federation)

^g CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^h Red Universitaria de Salud   (Canada)

ⁱ UNIVERSITY HOSPITAL ULM   (Germany)

^j UNIVERSITY OF PADOVA   (Italy)

^k RWTH AACHEN UNIVERSITY   (Germany)

more..

Author keywords

Abiraterone; Androgen deprivation; Chemotherapy; Denusomab; Docetaxel; EAU guidelines; Follow up; MDV3100; Prostate cancer; Review; Salvage radiation therapy; Salvage radical prostatectomy; Zoledronic acid

Indexed keywords

ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; GONADORELIN;

ADENOCARCINOMA; ARTICLE; CRYOSURGERY; DISEASE COURSE; DRUG ANTAGONISM; DRUG POTENTIATION; HUMAN; MALE; METASTASIS; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; ORCHIECTOMY; PATHOLOGY; PRACTICE GUIDELINE; PROSTATE TUMOR; PROSTATECTOMY; RADIOTHERAPY; SALVAGE THERAPY; TUMOR RECURRENCE;

ADENOCARCINOMA; ANDROGEN ANTAGONISTS; ANDROGENS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; CRYOSURGERY; DISEASE PROGRESSION; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; ORCHIECTOMY; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY; SALVAGE THERAPY;

EID: 80054680392     PISSN: 02104806     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acuro.2011.03.011     Document Type: Article

References (90)

1. A. Heidenreich, G. Aus, M. Bolla, S. Joniau, V.B. Matveev, and H.P. Schmich EAU guidelines on prostate cancer Eur Urol 53 2008 68 80 (Pubitemid 350166735)
2. Modied from Oxford Centre for Evidence-Based Medicine Levels of Evidence (May 2001). Produced by Bob Phillips, Chris Ball, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, and Martin Dawes since November 1998. CEBM. Disponible en: http://www. pdptoolkit.co.uk/Files/ebm/cebm/Doing%20ebm/levels- of-evidence. htm (consultado en noviembre de 2010).
3. D.G. McLeod Hormonal therapy: historical perspective to future directions Urology 61 2 Suppl 1 2003 3 74
4. J. Seidenfeld, D.J. Samson, V. Hasselblad, N. Aronson, P.C. Albertsen, and C.L. Bennett Single-therapy an-drogen suppression in men with advanced prostate cancer: a systematic review and meta-analysis Ann Intern Med 132 2000 566 577 (Pubitemid 30171897)
5. L. Klotz, L. Boccon-Gibod, N.D. Shore, C. Andreou, B.E. Persson, and P. Cantor The efcacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer BJU Int 102 2008 1531 1538
6. B. Tombal, K. Miller, L. Boccon-Gibod, F. Schröder, N. Shore, and E.D. Crawford Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics Eur Urol 57 2010 836 842
7. A.V. Kaisary, P. Iversen, C.J. Tyrrell, K. Carroll, and T. Morris Is there a role for antiandrogen monotherapy in patients with metastatic prostate cancer? Prost Cancer Prost Dis 4 2001 196 203 (Pubitemid 34048480)
8. C.J. Tyrrell, L. Denis, D. Newling, M. Soloway, K. Channer, and I.D. Cockshott Casodex1 10-200 mg daily, used as monotherapy for patients with advanced prostate cancer: an overview of the efcacy, tolerability and pharmacokinetics from three phase II dose-ranging studies. Casodex Study Group Eur Urol 33 1998 39 53 (Pubitemid 28033416)
9. C.J. Tyrrell, A.V. Kaisary, P. Iversen, J.B. Anderson, L. Baert, and T. Tammela A randomised comparison of 'Casodex1' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer Eur Urol 33 1998 447 456 (Pubitemid 28251992)
10. B. Schmitt, T.J. Wilt, P.F. Schellhammer, V. DeMasi, O. Sartor, and E.D. Crawford Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: a systematic review Urology 57 2001 727 732
11. J.W. Moul Twenty years of controversy surrounding combined an-drogen blockade for advanced prostate cancer Cancer 115 2009 3376 3378
12. N.A. Cruz Guerra Outcomes from the use of maximal androgen blockade in prostate cancer at health area with reference hospital type 2 (1st part). Quality of life: application of EORTC QLQ-C30 instrument Arch Esp Urol 62 2009 431 457
13. P.-A. Abrahamsson Potential benets of intermittent androgen suppression therapy in the treatment of prostate cancer: a systematic review of the literature Eur Urol 57 2010 49 59
14. M. Hussain, C.M. Tangen, C. Higano, P.F. Schelhammer, J. Faulkner, E.D. Crawford Southwest Oncology Group Trial 9346 (INT-0162) Absolute prostate-specic antigen value alter androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162) J Clin Oncol 24 2006 3984 3990 (Pubitemid 46630748)
15. E.Y. Yu, R. Gulati, D. Telesca, P. Jiang, S. Tam, and K.J. Russell Duration of rst off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation J Clin Oncol 28 2010 2668 2673
16. J. De Leval, P. Boca, E. Yousef, H. Nicolas, M. Jeukenne, and L. Seidel Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 1 2002 163 171 (Pubitemid 37012397)
17. F.E. Calais da Silva, A.V. Bono, P. Whelan, M. Brausi, A. Marques Queimadelos, and J.A. Martin Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group Eur Urol 55 2009 1269 1277
18. L. Boccon-Gibod, P. Hammerer, S. Madersbacher, N. Mottet, T. Prayer-Galetti, and U. Tunn The role of intermittent androgen deprivation in prostate cancer BJU Int 100 2007 738 743 (Pubitemid 47360177)
19. U.E. Studer, P. Whelan, W. Albrecht, J. Casselman, T. De Reijke, and D. Hauri Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891 J Clin Oncol 24 2006 1868 1876 (Pubitemid 46638985)
20. U.E. Studer, L. Collette, P. Whelan, W. Albrecht, J. Casselman, T. De Reijke EORTC Genitourinary Group Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891) Eur Urol 53 2008 941 949
21. F.H. Schröder, K.-H. Kurth, S.D. Fossa, W. Hoekstra, P.P. Karthaus, and L. De Prijck Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: nal results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial) Eur Urol 55 2009 14 22
22. J.W. Moul, H. Wu, L. Sun, D.G. McLeod, C. Amling, and T. Donahue Early versus delayed hormonal therapy for prostate specic antigen only recurrence of prostate cancer after radical prostatectomy J Urol 171 2004 1141 1147 (Pubitemid 38327544)
23. D.P. Byar Proceedings: the Veterans Administration Co-operative Urological Research Group studies of cancer of the prostate Cancer 32 1973 1126 1130
24. W.P. Jordan Jr., C.E. Blackard, and D.P. Byar Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma South Med J 70 1977 1411 1413
25. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997;79:235-6.
26. E.M. Messing, J. Manola, M. Sarosdy, G. Wilding, E.D. Crawford, and D. Trump Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer N Engl J Med 341 1999 1781 1788
27. Nair B, Wilt T, MacDonald R, Rutks I. Early versus deferred androgen suppression in the treatment of advanced prostatic cancer. Cochrane Database Syst Rev. 2002; CD003506.
28. E.M. Messing, J. Manola, J. Yao, M. Kiernan, D. Crawford, G. Wilding Eastern Cooperative Oncology Group study EST 3886 Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy Lancet Oncol 7 2006 472 479 (Pubitemid 43779173)
29. Y.N. Wong, S. Freedland, B. Egleston, G. Hudes, J.S. Schwartz, and K. Armstrong Role of androgen deprivation therapy for node-positive prostate cancer J Clin Oncol 27 2009 100 105
30. S.C. Morgan, and D.P. Dearnaley Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence? Expert Rev Anticancer Ther 9 2009 939 951
31. A. Serpa Neto, M. Tobias-Machado, M.A. Esteves, M.D. Senra, M.L. Wroclawski, and F.L. Fonseca A systematic review and meta-analysis of bone metabolism in prostate adeno-carcinoma BMC Urol 10 2010 9
32. H. Isbarn, L. Boccon-Gibod, P.R. Carroll, F. Montorsi, C. Schulman, and M.R. Smith Androgen deprivation therapy for the treatment of prostate cancer: consider both benets and risks Eur Urol 55 2009 62 75
33. C.C. Schulman, J. Irani, J. Morote, J.A. Schalken, F. Montorsi, and P.L. Chlosta Testosterone measurement in patients with prostate cancer Eur Urol 58 2010 65 74
34. J. Morote, S. Esquena, J.M. Abascal, E. Trilla, L. Cecchini, and C.X. Raventós Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinising hormone releasing hormone agonist therapy in patients with advanced prostate cancer Urol Int 77 2006 135 138 (Pubitemid 44195773)
35. M. Perachino, V. Cavalli, and F. Bravi Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic signicance? BJU Int 105 2010 648 651
36. J.E. Faris, and M.R. Smith Metabolic sequelae associated with androgen deprivation therapy for prostate cancer Curr Opin Endocrinol Diabetes Obes 17 2010 240 246
37. P.J. Saylor, and M.R. Smith Metabolic complications of androgen deprivation therapy for prostate cancer J Urol 181 2009 1998 2006
38. A.J. Stephenson, M.W. Kattan, J.A. Eastham, Z.A. Dotan, J. Bianco Jr, and H. Lilja Dening biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized denition J Clin Oncol 24 2006 3973 3978 (Pubitemid 46630746)
39. M. Roach 3rd, G. Hanks, H. Thames Jr., P. Schellhammer, W.U. Shipley, and G.H. Sokol Dening biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Biol Phys 65 2006 965 974
40. S.F. Slovin, A.S. Wilton, G. Heller, and H.I. Scher Time to detectable metastático disease in patients with rising prostate-specic antigen values following surgery or radiation therapy Clin Cancer Res 11 2005 8669 8673 (Pubitemid 43005915)
41. M.L. Cher, F.J. Bianco Jr., J.S. Lam, L.P. Davis, D.J. Grignon, and W.A. Sakr Limited role of radionuclide bone scintigraphy in patients with prostate specic antigen elevations after radical prostatectomy J Urol 160 1998 1387 1391 (Pubitemid 29480523)
42. C.J. Kane, C.L. Amling, P.A.S. Johnstone, N. Pak, R.S. Lance, and J.B. Thrasher Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy Urology 61 2003 607 611 (Pubitemid 36294200)
43. P. Gómez, M. Manoharan, S.S. Kim, and M.S. Soloway Radionuclide bone scintig-raphy in patients with biochemical recurrence after radical pros-tatectomy: when is it indicated? BJU Int 94 2004 299 302 (Pubitemid 39120167)
44. S. Cirillo, M. Petracchini, L. Scotti, T. Gallo, A. Macera, and M.C. Bona Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging Eur Radiol 19 2009 761 769
45. A.C. Westphalen, F.V. Coakley 3rd, M. Roach, C.E. McCulloch, and J. Kurhanewicz Locally recurrent prostate cancer after external beam radiation therapy: diagnostic performance of 1.5-T endorectal MR imaging and MR spectroscopic imaging for detection Radiology 256 2010 485 492
46. E. Pelosi, V. Arena, A. Skanjeti, V. Pirro, A. Douroukas, and A. Pupi Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse alter radical treatment for prostate cancer Radiol Med 113 2008 895 904
47. A.J. Breeuwsma, J. Pruim, A.C. Van den Bergh, A.M. Leliveld, R.J. Nijman, and R.A. Dierckx Detection of local, regional, and distant recurrence in patients with PSA relapse alter external-beam radiotherapy using (11)C-choline positron emission tomography Int J Radiat Oncol Biol Phys 77 2010 160 164
48. G. Giovacchini, M. Picchio, E. Coradeschi, V. Bettinardi, L. Gianolli, and V. Scattoni Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure alter radical prostatectomy Eur J Nucl Med Mol Imaging 37 2010 301 309
49. O. Schillaci, F. Calabria, M. Tavolozza, C. Cicci, M. Carlani, and C.R. Caracciolo 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer Nucl Med Commun 31 2010 39 45
50. A.J. Stephenson, P.T. Scardino, M.W. Kattan, T.M. Pisansky, K.M. Slawin, and E.A. Klein Predicting outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy J Clin Oncol 25 2007 2035 2041 (Pubitemid 46972788)
51. G.P. Swanson, M.A. Hussey, C.M. Tangen, J. Chin, E. Messing, and E. Canby-Hagino Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794 J Clin Oncol 25 2007 2225 2229 (Pubitemid 46954647)
52. B.J. Trock, M. Han, S.J. Freedland, E.B. Humphreys, T.L. DeWeese, and A.W. Partin Prostate cancer-specic survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy JAMA 299 2008 2760 2769 (Pubitemid 351846851)
53. G. Goldner, J. Dimopoulos, and R. Pötter Is the Roach formula predictive for biochemical outcome in prostate cancer patients with minimal residual disease undergoing local radiotherapy after radical prostatectomy? Radiother Oncol 94 2010 324 327
54. L.F. Da Pozzo, C. Cozzarini, A. Briganti, N. Suardi, A. Salonia, and R. Bertini Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy Eur Urol 55 2009 1003 1011
55. G.D. Grossfeld, Y.P. Li, D.P. Lubeck, J.M. Broering, S.S. Mehta, and P.R. Carroll Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor J Urol 168 2002 530 535 (Pubitemid 34793288)
56. A. Heidenreich, R. Semrau, D. Thüer, and D. Pfister Radical salvage prostatectomy: treatment of local recurrence of prostate cancer after radiotherapy Urologe A 47 2008 1441 1446
57. A.J. Stephenson, P.T. Scardino, F.J. Bianco Jr, C.J. DiBlasio, P.A. Fearn, and J.A. Eastham Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy J Urol 172 2004 2239 2243 (Pubitemid 39507499)
58. A. Heidenreich, C. Ohlmann, E. Ozgür, and U. Engelmann Functional and oncological outcome of salvage prostatectomy of locally recurrent prostate cancer following radiation therapy Urologe A 45 2006 474 481
59. A. Heidenreich, S. Richter, D. Thüer, and D. Pster Prognostic parameters, complications, and oncologic and functional outcome of salvage radical prostatectomy for locally recurrent prostate cancer after 21st-century radiotherapy Eur Urol 57 2010 437 445
60. A.J. Stephenson, and J.A. Eastham Role of salvage radical prostatectomy for recurrent prostate cancer after radiation therapy J Clin Oncol 23 2005 8198 8203 (Pubitemid 46211555)
61. L.L. Pisters, A.C. Von Eschenbach, S.M. Scott, D.A. Swanson, C.P. Dinney, and C.A. Pettaway The efcacy and complications of salvage cryotherapy of the prostate J Urol 157 1997 921 925 (Pubitemid 27066279)
62. R.D. Cespedes, L.L. Pisters, A.C. Von Eschenbach, and E.J. McGuire Long-term follow-up of incontinence and obstruction after salvage cryosurgical ablation of the prostate: results in 143 patients J Urol 157 1997 237 240 (Pubitemid 26414966)
63. M.L. Eisenberg, and K. Shinohara Partial salvage cryoablation of the prostate for recurrent prostate cancer after radiotherapy failure Urology 72 2008 1315 1318
64. L.L. Pisters, J.C. Rewcastle, B.J. Donnelly, F.M. Lugnani, A.E. Katz, and J.S. Jones Salvage prostate cryoablation: initial results from the cryo on-line data registry J Urol 180 2008 559 563
65. G.J. Bubley, M. Carducci, W. Dahut, N. Dawson, D. Daliani, and M. Eisenberger Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specic Antigen Working Group J Clin Oncol 17 1999 3461 3467 (Pubitemid 29517916)
66. M. Warmuth, T. Johansson, and P. Mad Systematic review of the efcacy and safety of high-intensity focussed ultrasound for the primary and salvage treatment of prostate cancer Eur Urol 58 2010 803 815
67. F.-J. Murat, L. Poissonnier, M. Rabilloud, A. Belot, R. Bouvier, and O. Rouviere Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer Eur Urol 55 2009 640 649
68. H.I. Scher, S. Halabi, I. Tannock, M. Morris, C.N. Sternberg, M.A. Carducci Prostate Cancer Clinical Trials Working Group Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group J Clin Oncol 26 2008 1148 1159
69. H.I. Scher, T.M. Beer, C.S. Higano, A. Anand, M.E. Taplin, and E. Efstathiou Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study Lancet 375 2010 1437 1446
70. D.C. Danila, M.J. Morris, J.S. De Bono, C.J. Ryan, S.R. Denmeade, and M.R. Smith Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer J Clin Oncol 28 2010 1496 1501
71. A. Manni, M. Bartholomew, R. Caplan, A. Boucher, R. Santen, and A. Lipton Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome J Clin Oncol 6 1988 1456 1466 (Pubitemid 19089035)
72. A.V. D'Amico, M.H. Chen, A.A. Renshaw, M. Loffredo, and P.W. Kantoff Interval to testosterone recovery after hormonal therapy for prostate cancer and risk of death Int J Radiat Oncol Biol Phys 75 2009 10 15
73. G. Di Lorenzo, C. Buonerba, R. Autorino, S. De Placido, and C.N. Sternberg Castration-resistant prostate cancer: current and emerging treatment strategies Drugs 70 2010 983 1000
74. Ryan C, Efstathiou E, Smith M, et al. Phase II multicenter study of chemotherapy (chemo)-naive castration-resistant prostate cancer (CRPC) not exposed to ketoconazole (keto), treated with abiraterone acetate (AA) plus prednisone. J Clin Oncol. 2009; 27:15s. Abstract 5046.
75. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, and M.E. Taplin Docetaxel and estra-mustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 2004 1513 1520 (Pubitemid 39315318)
76. I.F. Tannock, R. De Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi TAX 327 Investigators Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 2004 1502 1512 (Pubitemid 39315317)
77. J.M. Fitzpatrick, J. Anderson, C.N. Sternberg, N. Fleshner, K. Fizazi, and X. Rébillard Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach Crit Rev Oncol Hematol 68Suppl1 2008 S9 22
78. A.J. Armstrong, E. Garrett-Mayer, R. De Wit, I. Tannock, and M. Eisenberger Prediction of survival following rst-line chemotherapy in men with castration-resistant metastatic prostate cancer Clin Cancer Res 16 2010 203 211
79. Y. Loriot, C. Massard, M. Gross-Goupil, M. Di Palma, B. Escudier, and A. Bossi The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efcacy of subsequent docetaxel in patients with prostate cancer Eur J Cancer 46 2010 1770 1772
80. C. Buonerba, G. Palmieri, and G. Di Lorenzo Docetaxel rechallenge in castration-resistant prostate cancer: scientic legitimacy of common clinical practice Eur Urol 58 2010 636 637
81. J.C. Eymard, S. Oudard, G. Gravis, J.M. Ferrero, C. Theodore, and F. Joly Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study BJU Int 106 2010 974 978
82. Ohlmann CH, Markert E, Gerharz M, Dienes HP, Stöckle M, Engelmann U, et al. Improving the efcacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urol Oncol. 2009 Nov 24.
83. K. Fizazi, C.N. Sternberg, J.M. Fitzpatrick, R.W. Watson, and M. Tabesh Role of targeted therapy in the treatment of advanced prostate cancer BJU Int 105 2010 748 767
84. C.N. Sternberg, D.P. Petrylak, O. Sartor, J.A. Witjes, T. Demkow, and J.M. Ferrero Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial J Clin Oncol 27 2009 5431 5438
85. Sartor AO, Oudard S, Ozguroglu M, De Bono JS, Hansen S, Machiels JP, et al. para los TROPIC Investigators. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: Final results of a multinational phase III trial (TROPIC). 2010 Genitourinary Cancers Symposium. Abstract 9.
86. P.W. Kantoff, C.S. Higano, N.D. Shore, E.R. Berger, E.J. Small, D.F. Penson IMPACT Study Investigators Sipuleucel-T immunotherapy for castration-resistant préstate cancer N Engl J Med 363 2010 411 422
87. F. Saad, D.M. Gleason, R. Murray, S. Tchekmedyian, P. Venner, and L. Lacombe A randomized, placebo-controlled trial of zoledronic acid in patients with hormone refractory metastatic prostate carcinoma J Natl Cancer Inst 94 2002 1458 1468
88. Fizazi K, Carducci MA, Smith MR, Damião R, Brown JE, Karsh L, et al. A randomized phase III trial of denusomab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol. 28:343s. Abstract LBA4507.
89. J.M. Kuhn, T. Billebaud, H. Navratil, A. Moulonguet, J. Fiet, and P. Grise Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide) N Engl J Med 321 1989 413 418 (Pubitemid 19211483)
90. E.D. Crawford, M.A. Eisenberger, D.G. McLeod, B.A. Blumenstein, M.A. Davis, and P.J. Goodman A controlled trial of leuprolide with and without utamide in prostatic carcinoma N Engl J Med 321 1989 419 424 (Pubitemid 19211484)